New blood test detects early-stage pancreatic cancer with high accuracy

Researchers from the United States, China, Korea and Japan reported that the PANXEON blood test, which measures circulating and exosomal microRNAs together with the CA19-9 antigen and applies artificial-intelligence analysis, detected stage 1 and 2 pancreatic cancer in 87% of a cohort of roughly 1,800 participants. The assay showed a low false-positive rate—around 3% among low-risk individuals and 16% among those at higher risk—and identified high-grade dysplasia in about 64% of cases.

Experts highlighted that the test could serve as a triage tool for people already known to be at elevated risk, prompting earlier scans or endoscopic evaluation. While the findings suggest a potential shift toward earlier diagnosis, investigators caution that further longitudinal studies are needed before broad screening adoption. The study appears in Nature Medicine and adds to ongoing efforts to improve survival odds for a disease that currently sees only about 15% of patients eligible for curative surgery.